Related Experiment Videos
Calcium antagonists and the progression of chronic renal failure
1Department of Medicine, University of Miami School of Medicine, Florida, USA.
Abstract:
End-stage renal disease, which signifies irreversible renal failure, constitutes a major and growing public health problem worldwide. The striking increase in end-stage renal disease has catalyzed clinical and investigative focus on pharmacologic interventions to retard progression to this condition. Increasing evidence indicates that some classes of antihypertensive medications may confer a greater effect than others in slowing progression of renal disease despite similar levels of blood pressure reduction. Substantive data indicate that angiotensin converting enzyme inhibition preferentially retards the progression of renal disease, primarily by protecting the injured kidney from hemodynamically mediated glomerular damage. Newer studies suggest that calcium antagonists also have diverse properties, which are independent of their renal microcirculatory effects that might afford renal protection.
Insights
Certain antihypertensive drugs slow the progression of kidney disease. Angiotensin converting enzyme inhibitors show preferential renal protection, while calcium antagonists may offer additional benefits beyond blood pressure control.
Area of Science:
- Nephrology
- Pharmacology
- Public Health
Background:
- End-stage renal disease (ESRD) is a significant global health issue.
- The increasing incidence of ESRD necessitates effective pharmacologic interventions.
- Antihypertensive medications may differentially impact renal disease progression.
Purpose of the Study:
- To review the evidence on pharmacologic interventions for slowing ESRD progression.
- To compare the renal protective effects of different antihypertensive drug classes.
- To explore mechanisms of renal protection beyond blood pressure reduction.
Main Methods:
- Literature review of clinical studies and pharmacological data.
- Analysis of evidence regarding angiotensin converting enzyme inhibitors (ACEIs).
- Examination of newer data on calcium antagonists (CCBs).
Main Results:
- ACEIs demonstrate preferential retardation of renal disease progression.
- Renal protection by ACEIs is primarily attributed to mitigating glomerular damage.
- Calcium antagonists exhibit properties, independent of microcirculatory effects, that may protect the kidney.
Conclusions:
- Pharmacologic interventions play a crucial role in managing renal disease progression.
- ACEIs offer significant renal protection, particularly in preventing hemodynamically mediated damage.
- Further research into the diverse renal protective mechanisms of CCBs is warranted.